Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.75 USD
Change Today -0.035 / -4.46%
Volume 300.0
IRSB On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

iris biotechnologies inc (IRSB) Snapshot

Open
$0.75
Previous Close
$0.79
Day High
$0.75
Day Low
$0.75
52 Week High
09/30/14 - $2.25
52 Week Low
01/26/15 - $0.15
Market Cap
11.5M
Average Volume 10 Days
85.0
EPS TTM
$-0.08
Shares Outstanding
15.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IRIS BIOTECHNOLOGIES INC (IRSB)

Related News

No related news articles were found.

iris biotechnologies inc (IRSB) Related Businessweek News

No Related Businessweek News Found

iris biotechnologies inc (IRSB) Details

Iris Biotechnologies, Inc., a life science company, focuses on developing solutions for the detection and monitoring of monogenic and complex genomic diseases. The company intends to develop and commercialize nano-biochip technology platform using a convergence of scientific disciplines in nanotechnology, semiconductor manufacturing, microfluidics, chemistry, molecular biology, genetics, genomics, and information technology for diagnosis and treatment of breast cancer, neurological disorders, heart disease, diabetes, and other gene-related metabolic problems. It also seeks to develop and commercialize BioWindows, an artificial intelligence system, which includes a database comprising data fields for patient demographic information, personal medical history, family medical history, and gene expression information, as well as use BioWindows database to enable drug development, stem cell research, and evolving clinical applications. In addition, the company is working on gene markers for CancerChip and specific markers associated with prostrate, lung, liver, kidney, and ovarian cancers; and genes associated with schizophrenia, Alzheimer disease, autoimmune system disorders, and metabolic and drug metabolism disorders. Iris Biotechnologies, Inc. was founded in 1999 and is headquartered in Santa Clara, California.

7 Employees
Last Reported Date: 05/15/15
Founded in 1999

iris biotechnologies inc (IRSB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

iris biotechnologies inc (IRSB) Key Developments

Iris BioTechnologies Inc. Announces Management Appointments

Iris BioTechnologies Inc. announced joining of Dr. Douglas Hendren, Dr. John Hearst, Dr. Frank Chuang, and Gayle Murray to management team. Douglas Hendren, M.D., MBA, was elected to the Iris board of directors along with existing board members Simon Chin and Grace Osborne at the Iris annual shareholders meeting. Dr. Hendren served as Medical and Business Strategy Advisor since October 2013. Doug was a partner at Humboldt Orthopedics. He was a founding partner of Hess Orthopaedics, a managing partner, designer and the first director of the Hess surgical facility. John Hearst, Ph.D., has been appointed to the newly created position of Director of Clinical Chemistry. John is an Emeritus Professor of Chemistry at U.C. Berkeley. He was previously the founding director and vice president for New Science Opportunities at Cerus Corporation. Dr. Hearst mentored 65 graduate students, including Dr. Thomas Cech, who became a Nobel Laureate in Chemistry and the President of the Howard Hughes Medical Institute. Frank Chuang, Ph.D., M.D., has been appointed to the newly created position of Director of Clinical Applications. In this role, he will have broad responsibilities in clinical translation research and launching new products. He previously worked at Cornell Hospital for Special Surgery in rheumatologic disease, the Lawrence Livermore National Laboratory in their Medical Technology Program, and the Comprehensive Cancer Center, University of California, Davis. Gayle Murray has been appointed to the newly created position of Director of Marketing. As Iris prepares for product launch through its subsidiary, Iris Wellness Labs, Gayle will play a key role in both traditional as well as social media marketing. She was previously the U. C. Davis Account Executive with J. A. Majors Company.

Iris BioTechnologies Inc. Announces Board Elections

Iris BioTechnologies Inc. announced that at the Annual Meeting of Shareholders held on November 14, 2014 elected Simon Chin and Douglas Hendren as directors.

Iris BioTechnologies Inc., Annual General Meeting, Nov 14, 2014

Iris BioTechnologies Inc., Annual General Meeting, Nov 14, 2014., at 10:00 Pacific Daylight. Location: 5201 Great America Parkway. Agenda: To elect three members to board of directors; to ratify the appointment of Fiondella Milone and LaSaracina, LLP as independent registered public accounting firm for fiscal year ending December 31, 2014; and to transact such other matters as may properly come before the annual meeting and any adjournment or postponement thereof.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IRSB:US $0.75 USD -0.035

IRSB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IRSB.
View Industry Companies
 

Industry Analysis

IRSB

Industry Average

Valuation IRSB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IRIS BIOTECHNOLOGIES INC, please visit www.irisbiotech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.